<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1515">
  <stage>Registered</stage>
  <submitdate>1/04/2007</submitdate>
  <approvaldate>1/04/2007</approvaldate>
  <nctid>NCT00455026</nctid>
  <trial_identification>
    <studytitle>Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia</studytitle>
    <scientifictitle>Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005.236</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depth of Anaesthesia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - remifentanil

Placebo Comparator: 1 - 0 ng/ml target effect site concentration remifentanil

Active Comparator: 2 - 2 ng/ml target concentration remifentanil

Active Comparator: 3 - 4 ng/ml target effect site concentration remifentanil


Treatment: drugs: remifentanil
target effect site concentration during induction

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prediction probability for prediction of anaesthetic endpoints</outcome>
      <timepoint>During induction of anaesthesia</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female patients, aged 18-60 years, of ASA physical status 1-3, presenting for
             elective surgery under general anaesthesia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inadequate English comprehension due to a language barrier, cognitive deficit or
             intellectual disability

          -  Epilepsy or other EEG abnormality

          -  Prescription or illicit drugs known to affect the EEG</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>45</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Swinburne University - Hawthorn</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3123 - Hawthorn</postcode>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Biopharmica Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Current cortical EEG based depth of anaesthesia monitors do not accurately reflect the effect
      of opioid drugs. We have developed a new theoretically-based method of analysing the EEG. Our
      hypothesis is that this new method will more accurately predict depth of anaesthesia than the
      Bispectral Index (BIS) monitor in patients having elective surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00455026</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kate Leslie, MD</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>